This is an original U.S. patent application.
The present invention relates generally to medical devices, and more particularly to apparatus for and methods of supporting and stabilizing or dilating external tissue in humans. As disclosed and taught in the preferred embodiments, the tissue dilator devices are particularly suitable for, and are directed primarily to, external nasal dilators for supporting, stabilizing, and dilating nasal outer wall tissues adjacent and overlying nasal airway passages of the human nose. The United States Food and Drug Administration classifies the external nasal dilator as a 510(K) Exempt [Medical] Device Class r, product code LWF, regulation No. 874,3900.
External nasal dilators (END) are well disclosed in the art and are widely available in the retail consumer markets where they are generally referred to as nasal strips or nasal dilator strips. In use the END extends over the skin surfaces of the nose, flexed across the bridge thereof and adhered to the skin surface of the nasal passage outer wall tissues on each side of the bridge.
The functional part of the END is at least one resilient member (synonymously referred to in the art as a spring, spring member, resilient band, resilient member band, spring band, or bridge) that extends along the length of the nasal dilator. When flexed, the resilient member exerts spring biasing forces that, when engaged to the nose, urge the nasal passage outer wall tissues outward, stabilizing the outer walls and expanding, or dilating, the nasal passages underneath.
Stabilized nasal outer walls and/or dilated nasal passages may beneficially affect nasal obstruction and nasal congestion by reducing nasal airflow resistance. Stabilized nasal outer walls inhibit collapse of the outer wall tissues during inhalation. Dilated nasal passages increase cross sectional area and nasal cavity volume. Stabilization and/or dilation, particularly at the nasal valve, results in a corresponding improvement in nasal breathing patency. Improved nasal patency may have beneficial effects generally, may increase oxygen uptake, may improve sleep, may reduce sleep disturbances, or may improve nasal snoring or obstructive sleep apnea (OSA). External nasal dilators have been shown to have beneficial effects for athletes, particularly in sports where a mouth-guard is worn.
Nasal dilators of the present invention are capable of flexing in a direction oblique or perpendicular to a surface place thereof, such that the dilator returns to a substantially planar or pre-flexed state when released from flexure. In use the dilator stabilizes portions of the tissues extending along and adjacent the nasal passages and prevents, or at least inhibits, the tissues from drawing inward during breathing, particularly at the nasal valve. The dilator expands, or dilates, the nasal passages. The nasal dilator adheres comfortably to skin surface of the nose and is easily removed with little or no stress thereto.
Nasal dilators of the present invention use spring finger components extending outward from a resilient member mid-section component to engage multiple discrete dilation points overlaid or adjacent along the first and second nasal passages. Resiliency, or spring biasing forces, generated by the nasal dilator is distributed from the resilient member mid-section to the spring fingers, and by extension, to the multiple discrete dilation points: upper spring fingers extend up and away from the nasal valve area; middle spring fingers extend substantially over and in line with the nasal valve; lower spring fingers extend away and downward from the nasal valve area to the nasal vestibule area toward the nostril opening.
By directing total spring biasing forces in this manner, stabilization and/or dilation is directed to a greater portion of the nasal passages compared to a nasal dilator in which a substantially rectangular resilient member(s) overlays only the tissues directly over the nasal valve. The nasal dilator resilient element may be longitudinally separated into two or three individual resilient members, or a single resilient member may be slotted to form from three to six resilient branches extending horizontally outward from near the center of the mid-section. Additionally, first and second end regions of the nasal dilator are configured to extend around the curvature of the nostril so as to avoid spanning the anatomical depression formed by the alar crease of the nose.
Nasal dilators of the present invention have separate resilient and engagement elements combined into a single body truss. The engagement element functions primarily to affix, adhere, or engage the dilator to the skin surfaces of the nose. The engagement element, by itself, provides little or no nasal dilation (although depending on the material used, could provide some stabilization to the nasal passage outer walls). The resilient element, by itself and flexed across the bridge of the nose, generally will not remain well-engaged thereto. Thus, nasal dilators of the present invention preferably comprise both resilient and engagement elements.
The nasal dilator, formed as a single body truss, comprises a laminate of vertically stacked material layers, including: a base layer comprising at least one base member, a resilient layer comprising at least one resilient member, and a cover layer comprising at least one cover member. The base and cover layers, either separately or combined, together with a biocompatible adhesive disposed thereon for engaging the skin, provide the primary engagement element of the nasal dilator. Where the base layer has significantly less surface area than the cover layer, adhesive on the skin-engaging side of the base layer may be optionally eliminated. With or without adhesive, the base layer may also serve as a compressible buffer between the nasal dilator and the skin engaged thereby, as has been historically common in medical devices which remain in contact with the skin for any length of time. The resilient layer may optionally adhesively engage the skin directly.
Dilator layers may be secured to each other by any suitable means such as stitching or fastening, heat or pressure bonding, ultrasonic welding, or the like, but are preferably laminated by an adhesive substance disposed on at least one flat surface side of at least one layer. At least a portion of one flat surface of the base or cover layer is preferably laminated to one of two flat surfaces of the resilient layer.
The terms spring biasing, spring biasing force, spring force, resiliency, spring constant, etc. as used herein are generally synonymous. Nasal dilators of the present invention may generate spring biasing force in a range of from about 15 grams to about 60 grams. A preferred range is from about 15 grams to about 35 grams for non-athletes, and from about 25 grams to about 45 grams for use in training, conditioning and competition by athletes. Less than 15 grams of spring biasing may not provide enough stabilization or dilation for some users, while greater than 35 grams may be uncomfortable for non-athletic use, such as during sleep, work or study.
The nasal dilator resilient member is semi-rigid; it is flexible out-of-plane with very little or no in-plane elongation. Strictly speaking, the term resilient may be used to describe objects that exhibit either ‘flexure’ or ‘elasticity’. For purposes of the present invention, however, the terms resilient, resiliency, spring biasing, etc., mean flexure out-of-plane, in a direction perpendicular or oblique to the surface plane, while being substantially rigid in-plane. This is different from, for example, an elastic web that stretches in a direction parallel to its surface plane, even though both the elastic web and the nasal dilator resilient member may return at least substantially to their initial positions after stretch or flexure, respectively. Nasal dilators herein may be described as “capable of flexing” (when the dilator is in an initial or un-flexed position), or “flexed” (when the dilator is engaged to the nose of a user).
The present invention is not limited to the illustrated or described embodiments, which are examples of forms of the present invention. All structures and methods that embody similar functionality are intended to be covered hereby. The nasal dilators depicted, taught, enabled and disclosed herein represent new, useful and non-obvious nasal dilator devices having a variety of alternative embodiments. Some embodiments of the present invention may refer to, or cross reference, other embodiments. It may be apparent to one of ordinary skill in the art that nasal dilator features, construction or configuration may be applied, interchanged or combined between and among the preferred embodiments.
For descriptive clarity, certain terms may be used in the specification and claims: Vertical refers to a direction parallel to thickness, such as the thickness of a finished article, a member or component, or a laminate. Horizontal refers to length or longitudinal extent, such as that of a finished article or element thereof, or a direction parallel thereto. Lateral refers to its width or lateral extent. Longitudinal also refers to length, perpendicular to width or lateral extent. A longitudinal centerline is consistent with the long axis of a finished device, element, member or layer, bisecting its width midway between the long edges. A lateral centerline bisects the long axis midway along its length, perpendicular to the longitudinal centerline. The terms upper and lower refer to object orientation, particularly in plan views, relative to the top and bottom of the drawing sheet.
Broken lines and dashed lines may be used in the drawings to aid in describing relationships or circumstances with regard to objects:
In the drawings accompanying this disclosure like objects are generally referred to with common reference numerals or characters, except where variations of otherwise like objects must be distinguished from one another. Where there is a plurality of like objects in a single drawing figure corresponding to the same reference numeral or character, only a portion of said like objects may be identified. After initial description in the text, some reference characters may be placed in a subsequent drawing(s) in anticipation of a need to call repeated attention to the referenced object. Where a feature or element has been previously described, shadow lines, or dashed lines, may be used to generically illustrate the feature or element together with a generic reference character. Drawings are rendered to scale—particularly plan views—but may be enlarged from actual size for illustrative clarity. Similarly, thickness may be slightly exaggerated for illustrative clarity.
Embodiments of a nasal dilator, 10, in accordance with the present invention are illustrated in
The peripheral dimensions of dilator 10 may be defined by the cover layer, the base layer, or a combination thereof. As seen in
Dilator layers may be stacked, or vertically arranged such that the base and cover layers are reversed, or the base layer or cover layer may be eliminated in whole or in part. As seen in
The preferred materials for the base and cover members may be selected from a range of widely available, preferably medical grade, flexible nonwoven synthetic fabrics or thermoplastic films that are, most preferably, breathable and comfortable on the skin. Any suitable fabric or thermoplastic film, including high Moisture Vapor Transmission Rate (MVTR) polyurethane film, may be used. A pressure sensitive adhesive, preferably biocompatible with external human tissue, may be disposed on at least one flat surface side of the material, in which case a protective, removable, release liner may cover the adhesive to protect it until the user is ready to apply the device.
The at least one resilient member 22 provides resiliency in the form of spring biasing forces as discussed hereinbefore. Resiliency is defined herein as being flexible out-of-plane while remaining substantially rigid in-plane when the dilator is flexed across the bridge of the nose. The preferred material for the resilient member is a thermoplastic resin, which may be selected from a range of thermoplastics having flexural, tensile and elastic moduli so as to have substantial in-plane rigidity and out-of-plane flexibility such that the resilient member has suitable spring biasing properties at a thickness, for example, of from about 0.005″ to about 0.015″. The most preferred thermoplastic material is a biaxially oriented polyester resin, Poly(ethylene terephthalate) or PET (or boPET). PET is used in a number of medical device applications, is particularly suitable for nasal dilator devices, and is widely available as a medical/industrial commodity.
The combined layers of dilator to form a unitary, or single body, truss.
Resilient member 22 includes a plurality of spring finger components, 23a, 23b and 23c, extending outward from each end of the resilient member mid-section, 21. These are identified in
Spring fingers 23 extend outward with, and are adjacent to, engagement element tab extensions, 30a, 30b, 30c and 30d. Thick, dark lines in
As depicted in
As seen particularly in
The total resiliency, or spring biasing forces, distributed by dilator 10 extend through mid-section 21 and spring fingers 23 to multiple discrete dilation points along the first and second nasal passages, as described hereinbefore. These dilation points are associated with several muscles about nose 11, as shown in
As more particularly seen in
The engagement element, e, of dilator 10 may be depicted by shadow lines, as seen in
An anatomical depression, or valley, d, adjacent each nostril of nose 11 is shown by stippling in
It will be apparent to one of ordinary skill in the art that where a portion of nasal dilator surface area extends across or spans the anatomical depression, the nasal dilator will thus be non-engaged to the skin surface thereat. Areas of non-engagement can lead to the nasal dilator having a greater propensity to prematurely disengage, or peel, from the nose during use. Accordingly, the end regions of dilator 10 are configured to extend around, and particularly, to avoid extending across, or spanning, valley d, so as to maximize skin surface contact of dilator 10 to nose 11.
The resilient layer of dilator 10 may be bisected lengthwise into two parts, as described hereinbefore, to form separate resilient members 22a and 22b, as seen in
In lieu of being bisected lengthwise into two parts, a single resilient member 22 may be slotted to form four resilient branches.
The resilient layer of dilator 10 may be trisected lengthwise into three separate resilient members, 22a, 22b and 22c, as illustrated in
A single resilient member 22 may be notched and/or slotted to form six resilient branches extending outward from the center of mid-section 21, as seen in
Bisecting or slotting the resilient element allows dilator 10 to have greater overall axial/torsional flexibility about its longitudinal centerline. Greater flexibility allows dilator 10 to better conform to contours of the nose and to better balance spring biasing forces between tab extensions 30a/30b and 30c/30d, respectively, on each side of the centerline. Additionally, a slotted resilient member 22 forms a contiguous area extending between the long edges at the center of mid-section 21. The contiguous area may generate greater spring biasing forces thereat compared to a bisected/trisected resilient layer.
As shown in
These prior art nasal dilators have very similar resiliency to that of dilator 10: U.S. Pub. No. 20110000483 teaches that “The total spring force delivered by the resilient element as a whole should be from about 15 grams (gm) to about 60 gm. In one embodiment, the total spring force delivered by the resilient element as a whole should be from 25 gm to about 35 gm.” U.S. Pat. No. 5,533,503 teaches that “A desired functional range of dilating force (i.e., the spring biasing force due to the resiliency of the resilient means of the nasal dilator) is typically in the range of 5 to 50 grams . . . The nasal dilator 10, of the present invention, is constructed to produce from 20 to 30 grams of dilating spring biasing force . . . ” (Additionally, U.S. Pat. No. 5,533,503 provides dimensions for its two resilient members: “The first and second resilient hands 30a and 30b are each formed of a plastic material . . . that is approximately 0.080″ to 0.135″ wide and 0.010″ thick.”) The range of spring biasing force delivered by nasal dilators of the present invention, as described herein, is substantially the same as the prior art nasal dilators.
Nasal dilators of the present invention apply spring biasing forces to a greater area of the nasal passages, and withstand the same or greater spring biasing forces compared to the prior art nasal dilators, due to greater end region width and greater surface area formed by the configuration of spring fingers 23 and tab extensions 30. The prior art dilators include upper and lower tab extensions x one to each outermost side of either two or three parallel adjacent resilient members. By comparison, nasal dilators of the present invention have three or four spring fingers interposed between four tab extensions at each end region.
A standard unit of measure (1.0) is used in
It may be apparent to those of ordinary skill in the art that, since the length of an external nasal dilator generally spans the width of the average human adult nose from nostril to nostril, there is relatively little difference in the l dimension between the prior art nasal dilators and nasal dilators of the present invention; that difference is less than 10%. However, there are significant differences in the o and w dimensions between dilator 10 and the prior art nasal dilators. For example, dilator 10 of
Thus there are significant differences in aspect ratios l:o and l:w between the prior art nasal dilators and nasal dilators of the present invention, as detailed in the table and charts below. (For this purpose, width dimensions o and w are expressed as l; overall length l is expressed as a multiple thereof.) For example, the ratio of overall length to overall width of the prior art two-band nasal dilator is 3.42:1, and its ratio of overall length to resilient element width is 7.44:1. That is, the overall length of the prior art two-band nasal dilator is 3.42 times greater than its overall width, and is 7.44 times greater than its resilient element width:
Nasal dilators of the present invention have an aspect ratio of overall length to overall width (l:o) that is somewhat lesser than that of the prior art nasal dilators, as more particularly illustrated in the first chart at
Furthermore, the aspect ratios of overall length to resilient element width (l:w) is considerably lesser in nasal dilators of the present invention compared to the prior art nasal dilators, as shown in the second chart at
Accordingly, nasal dilators of the present invention have a preferred aspect ratio of overall length to overall width (l:o) in a range of from about 1.80-2.50 to 1, wherein the ho aspect ratios of the prior art nasal dilators are outside this range, being from 2.70-3.42 to 1.
Additionally, the preferred aspect ratio of overall length to resilient element width (l:w) of dilator 10 is in a range of from about 2.50-3.80 to 1, wherein the l:w aspect ratios of the prior art nasal dilators are well outside this range, being from 50.46-70.44 to 1.
As illustrated and described in examples of the preferred embodiments, the present invention provides novel and non-obvious articles for dilating external tissue, particularly in the form of external nasal dilator devices.
Number | Name | Date | Kind |
---|---|---|---|
5476091 | Johnson | Dec 1995 | A |
5479944 | Petruson | Jan 1996 | A |
5533499 | Johnson | Jul 1996 | A |
5533503 | Doubek et al. | Jul 1996 | A |
5546929 | Muchin | Aug 1996 | A |
5549103 | Johnson | Aug 1996 | A |
RE35408 | Petruson | Dec 1996 | E |
5611333 | Johnson | Mar 1997 | A |
5653224 | Johnson | Aug 1997 | A |
5706800 | Cronk et al. | Jan 1998 | A |
5718224 | Muchin | Feb 1998 | A |
5769089 | Hand et al. | Jun 1998 | A |
5890486 | Mitra et al. | Apr 1999 | A |
5931854 | Dillon | Aug 1999 | A |
5957126 | Neeser | Sep 1999 | A |
6006746 | Karell | Dec 1999 | A |
6029658 | De Voss | Feb 2000 | A |
6058931 | Muchin | May 2000 | A |
6065470 | Van Cromvoirt et al. | May 2000 | A |
6098616 | Lundy et al. | Aug 2000 | A |
6196228 | Kreitzer et al. | Mar 2001 | B1 |
6244265 | Cronk et al. | Jun 2001 | B1 |
6276360 | Cronk et al. | Aug 2001 | B1 |
6318362 | Johnson | Nov 2001 | B1 |
6352548 | Blach | Mar 2002 | B1 |
6357436 | Kreitzer et al. | Mar 2002 | B1 |
6375667 | Ruch | Apr 2002 | B1 |
6453901 | Ierulli | Sep 2002 | B1 |
6470883 | Beaudry | Oct 2002 | B1 |
6550474 | Anderson et al. | Apr 2003 | B1 |
6694970 | Spinelli et al. | Feb 2004 | B2 |
6769428 | Cronk et al. | Aug 2004 | B2 |
6769429 | Benetti | Aug 2004 | B1 |
7067710 | Beaudry | Jun 2006 | B1 |
7114495 | Lockwood, Jr. | Oct 2006 | B2 |
D639762 | Brogden et al. | Jun 2011 | S |
D644325 | Brunner et al. | Aug 2011 | S |
D644324 | Brunner et al. | Oct 2011 | S |
8047201 | Guyuron et al. | Nov 2011 | B2 |
8062329 | Ierulli | Nov 2011 | B2 |
D651710 | Brogden et al. | Jan 2012 | S |
8115049 | Beaudry | Feb 2012 | B2 |
D659245 | Ierulli | May 2012 | S |
8188330 | Beaudry | May 2012 | B2 |
D662203 | Smith | Jun 2012 | S |
D667543 | Ierulli | Sep 2012 | S |
D671643 | Ierulli | Nov 2012 | S |
D672461 | Brogden et al. | Dec 2012 | S |
D672872 | Brunner et al. | Dec 2012 | S |
D673270 | Brunner et al. | Dec 2012 | S |
8342173 | Lockwood, Jr. | Jan 2013 | B2 |
8444670 | Ierulli | May 2013 | B2 |
8584671 | Ierulli | Nov 2013 | B2 |
8616198 | Guyuron et al. | Dec 2013 | B2 |
8617199 | Eull et al. | Dec 2013 | B2 |
8641852 | Ierulli | Feb 2014 | B2 |
D707814 | Ierulli | Jun 2014 | S |
D707815 | Ierulli | Jun 2014 | S |
8834511 | Holmes et al. | Sep 2014 | B2 |
8834512 | Brown et al. | Sep 2014 | B1 |
8834514 | Smith | Sep 2014 | B2 |
8858587 | Ierulli | Oct 2014 | B2 |
D722161 | Reyers | Feb 2015 | S |
D722162 | Reyers | Feb 2015 | S |
D725772 | Ierulli | Mar 2015 | S |
D725773 | Ierulli | Mar 2015 | S |
9095422 | Gray | Aug 2015 | B2 |
D738496 | Peck | Sep 2015 | S |
D739015 | Martin | Sep 2015 | S |
9119620 | Peterson et al. | Sep 2015 | B2 |
D741997 | Ierulli | Oct 2015 | S |
D741998 | Martin | Oct 2015 | S |
D743544 | Ierulli | Nov 2015 | S |
D743545 | Ierulli | Nov 2015 | S |
D743565 | Engel et al. | Nov 2015 | S |
D745147 | Ierulli | Dec 2015 | S |
9204988 | Fischell | Dec 2015 | B1 |
D746982 | Ierulli | Jan 2016 | S |
D747478 | Brunner et al. | Jan 2016 | S |
D753294 | Guyuron et al. | Apr 2016 | S |
D755376 | Ierulli | May 2016 | S |
D758575 | Ierulli | Jun 2016 | S |
D758576 | Ierulli et al. | Jun 2016 | S |
D759240 | Ierulli | Jun 2016 | S |
D759241 | Ierulli | Jun 2016 | S |
D759242 | Ierulli | Jun 2016 | S |
9364367 | Ierulli | Jun 2016 | B2 |
9364368 | Ierulli | Jun 2016 | B2 |
9381332 | Judd | Jul 2016 | B2 |
D764055 | Ierulli et al. | Aug 2016 | S |
D764662 | Ierulli et al. | Aug 2016 | S |
9414957 | Fischell | Aug 2016 | B1 |
9427945 | Gray et al. | Aug 2016 | B2 |
D779666 | Ierulli et al. | Feb 2017 | S |
D779667 | Ierulli et al. | Feb 2017 | S |
9566183 | Fischell | Feb 2017 | B1 |
D788298 | Guyuron | May 2017 | S |
9642995 | Fenton et al. | May 2017 | B2 |
D789531 | Ierulli | Jun 2017 | S |
D790058 | Ierulli et al. | Jun 2017 | S |
D790695 | Ierulli | Jun 2017 | S |
D791312 | Peck | Jul 2017 | S |
D791314 | Ierulli | Jul 2017 | S |
9730827 | Ierulli | Aug 2017 | B2 |
9730828 | Ierulli | Aug 2017 | B2 |
9775738 | Andre | Oct 2017 | B2 |
9844456 | Ierulli | Dec 2017 | B2 |
9901479 | Holmes | Feb 2018 | B2 |
9901480 | Ierulli | Feb 2018 | B2 |
9901481 | Ierulli | Feb 2018 | B2 |
D812749 | Ierulli | Mar 2018 | S |
D813387 | Ierulli et al. | Mar 2018 | S |
D814029 | Ierulli | Mar 2018 | S |
10010442 | Ierulli | Jul 2018 | B2 |
20080058858 | Smith | Mar 2008 | A1 |
20080097517 | Holmes et al. | Apr 2008 | A1 |
20090125052 | Pinna et al. | May 2009 | A1 |
20090234383 | Ierulli | Sep 2009 | A1 |
20100210988 | Dallison | Aug 2010 | A1 |
20100298861 | Fenton | Nov 2010 | A1 |
20110000483 | Matthias et al. | Jan 2011 | A1 |
20110054517 | Holmes et al. | Mar 2011 | A1 |
20110166594 | Eull | Jul 2011 | A1 |
20110224717 | Lockwood | Sep 2011 | A1 |
20120004683 | Gray | Jan 2012 | A1 |
20120022582 | Guyuron | Jan 2012 | A1 |
20120067345 | Shilon | Mar 2012 | A1 |
20120172923 | Fenton | Jul 2012 | A1 |
20120209313 | Ierulli | Aug 2012 | A1 |
20120232455 | Beaudry | Sep 2012 | A1 |
20130104882 | Ierulli | May 2013 | A1 |
20130118488 | Ledogar | May 2013 | A1 |
20140194922 | Ierulli | Jul 2014 | A1 |
20140148844 | Andre | Oct 2014 | A1 |
20140296904 | Andre | Oct 2014 | A1 |
20140350596 | Smith | Nov 2014 | A1 |
20150005812 | Holmes | Jan 2015 | A1 |
20150012035 | Ierulli | Jan 2015 | A1 |
20150051636 | Lockwood | Feb 2015 | A1 |
20150090398 | Ierulli | Apr 2015 | A1 |
20150090399 | Ierulli | Apr 2015 | A1 |
20150094757 | Ierulli | Apr 2015 | A1 |
20150094758 | Ierulli | Apr 2015 | A1 |
20150216709 | Peck | Aug 2015 | A1 |
20150230966 | Ierulli | Aug 2015 | A1 |
20150250637 | Ierulli | Sep 2015 | A1 |
20150290021 | Gray | Oct 2015 | A1 |
20150359654 | Bentivegna et al. | Dec 2015 | A1 |
20160008161 | Ierulli et al. | Jan 2016 | A1 |
20160278967 | Ierulli | Sep 2016 | A1 |
20160278968 | Ierulli | Sep 2016 | A1 |
20160339619 | Gray et al. | Nov 2016 | A1 |
20170112653 | Ierulli | Apr 2017 | A9 |
20170143531 | Ierulli | May 2017 | A9 |
20170151084 | Ierulli | Jun 2017 | A9 |
20180021163 | Ierulli | Jan 2018 | A9 |
20180028346 | Ierulli | Feb 2018 | A1 |
20180071131 | Ierulli | Mar 2018 | A1 |
Number | Date | Country |
---|---|---|
855175 | Jul 1998 | EP |
289561 | Oct 1985 | ES |
Number | Date | Country | |
---|---|---|---|
20200121488 A1 | Apr 2020 | US |